Antiviral Treatment of Myocarditis and Acute Dilated Cardiomyopathy

Heart Failure Clinics

Volumn 1, Issue 3, 2005, Pages 467-474

  Kühl, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIODARONE; ANTIVIRUS AGENT; BENEFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GAMMA INTERFERON; GLYCOSIDE; SPIRONOLACTONE; WARFARIN;

ADENOVIRUS; ANGINA PECTORIS; ARTHRALGIA; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DISEASE ASSOCIATION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG POTENCY; DYSPNEA; ENTEROVIRUS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART MUSCLE BIOPSY; HUMAN; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; INJECTION SITE REACTION; MORTALITY; MYALGIA; MYOCARDITIS; NAUSEA; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CARDIOMYOPATHY, DILATED; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MYOCARDITIS;

EID: 33645962514     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.06.014     Document Type: Review

References (54)

1. Michels V., Moll P., Miller F.A., et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 326 (1992) 77-82
2. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies [news]. Circulation 93 (1996) 841-842
3. Kühl U., Pauschinger M., Bock T., et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108 (2003) 945-950
4. Feldmann A.M., and McNamara D. Myocarditis. N Engl J Med 343 (2000) 1388-1398
5. Bowles N.E., Richardson P.J., Olsen E.G., et al. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1 (1986) 1120-1123
6. Why H.J., Meany B.T., Richardson P.J., et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 89 (1994) 2582-2589
7. Baboonian C., and Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 78 (1997) 539-543
8. Pauschinger M., Bowles N.E., Fuentes-Garcia F.J., et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99 (1999) 1348-1354
9. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (2003) 857-863
10. Matsumori A. Hepatitis C virus and cardiomyopathy. Intern Med 40 (2001) 78-79
11. Kuhl U., Pauschinger M., Noutsias M., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111 (2005) 887-893
12. Kuhl U., Pauschinger M., Bock T., et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108 (2003) 945-950
13. Kandolf R., Ameis D., Kirschner P., et al. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 84 (1987) 6272-6276
14. Li Y., Bourlet T., Andreoletti L., et al. Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation 101 (2000) 231-234
15. Bultmann B.D., Klingel K., Sotlar K., et al. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 34 (2003) 92-95
16. Vallbracht K.B., Schwimmbeck P.L., Kühl U., et al. Differential aspects on endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation and myocardial leukocyte infiltrates. Circulation 111 14 (2005) 1784-1791
17. Tschope C., Bock C.T., Kasner M., et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 111 (2005) 879-886
18. Noutsias M., Fechner H., de Jonge H., et al. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation 104 (2001) 275-280
19. Poller W., Fechner H., Noutsias M., et al. Highly variable expression of virus receptors in the human cardiovascular system. Implications for cardiotropic viral infections and gene therapy. Z Kardiol 91 (2002) 978-991
20. McCarthy R.E., Boehmer J.P., Hruban R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 (2000) 690-695
21. Freeman G.L., Colston J.T., Zabalgoitia M., et al. Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol 274 (1998) H249-H258
22. Lowenstein C.J., Hill S.L., Lafond Walker A., et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 97 (1996) 1837-1843
23. Bachmaier K., Neu N., Pummerer C., et al. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 96 (1997) 585-591
24. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1152
25. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387-389
26. Torre Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
27. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28 (1996) 964-971
28. Bozkurt B., Kribbs S.B., Clubb Jr. F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97 (1998) 1382-1391
29. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 (1999) 1091-1100
30. Dec G.W., and Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 331 (1994) 1564-1575
31. Pauschinger M., Doerner A., Kuehl U., et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99 (1999) 889-895
32. Fujioka S., Kitaura Y., Ukimura A., et al. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 36 (2000) 1920-1926
33. Wessely R., Henke A., Zell R., et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 98 (1998) 450-457
34. Klingel K., and Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 88 (1993) 79-85
35. Liu P., Aitken K., Kong Y., et al. The tyrosine kinase p56Ick is essential in coxsackievirus B3-mediated heart disease. Nat Med 6 (2000) 429-434
36. Pauschinger M., Doerner A., Kuehl U., et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99 (1999) 889-895
37. Badorff C., Noutsias M., Kühl U., et al. Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 29 (1997) 429-434
38. Schulze K., Witzenbichler B., Christmann C., et al. Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res 44 (1999) 91-100
39. Doerner A., Pauschinger M., Schwimmbeck P.L., et al. The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol 35 (2000) 1778-1784
40. Badorff C., Lee G.H., Lamphear B.J., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
41. Mann D.L., and Taegtmeyer H. Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart: recovering the missing link in left ventricular remodeling. Circulation 104 (2001) 1089-1091
42. Libby P., and Lee R.T. Matrix matters. Circulation 102 (2000) 1874-1876
43. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 (2000) 214-224
44. Thomas C.V., Coker M.L., Zellner J.L., et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
45. Szotowski B., Goldin-Lang P., Antoniak S., et al. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol 45 (2005) 1081-1089
46. Dec Jr. G.W., Palacios I.F., Fallon J.T., et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312 (1985) 885-890
47. Grogan M., Redfield M.M., Bailey K.R., et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 26 (1995) 80-84
48. Baron S. Introduction to the interferon system. In: Baron S. (Ed). Interferon: principles and medical applications (1992), The University of Texas Medical Branch at Galveston, Dept. of Microbiology, Galveston (TX) 1-15
49. Stille-Siegener M., Heim A., and Figulla H.R. Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J 16 Suppl O (1995) 147-149
50. Heim A., Stille-Siegener M., Kandolf R., et al. Enterovirus-induced myocarditis: hemodynamic deterioration with immunosuppressive therapy and successful application of interferon- alpha. Clin Cardiol 17 (1994) 563-565
51. Miric M., Vasiljevic J., Bojic M., et al. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 75 (1996) 596-601
52. Heim A., Canu A., Kirschner P., et al. Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J Infect Dis 166 (1992) 958-965
53. Matsumori A., Tomioka N., and Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 115 (1988) 1229-1232
54. Kuhl U., Pauschinger M., Schwimmbeck P.L., et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 (2003) 2793-2798